M54.50 Insurance Policy Changes

ICD-10 M54.50 is officially defined as "Low back pain, unspecified." code M54.50 is referenced in 16 tracked payer policy changes from Aetna and Blue Cross & Blue Shield of Mississippi. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M54.50 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Aetna · Identified Oct 26, 2026Medium impact
Pulsed Radiofrequency (CPB 0735, reviewed 2026-10-21)
Aetna's Clinical Policy Bulletin 0735 considers pulsed radiofrequency experimental, investigational, or unproven for all indications in its list, because its effectiveness has not been established. The list includes indications such as carpal tunnel syndrome, chronic knee pain, low back pain, trigeminal neuralgia, and headache. The policy also considers the Stimpod NMS460 nerve stimulator for post-amputation pain, combined ganglion impar block and pulsed radiofrequency for pudendal neuralgia, and combined platelet-rich plasma to the Gasserian ganglion and pulsed radiofrequency for trigeminal neuralgia experimental, investigational, or unproven.
Aetna · Identified Oct 17, 2026Medium impact
Chronic Pelvic Pain and Endometriosis (CPB 0754, reviewed 2026-10-16)
Aetna considers cannabinoids, hypnotherapy, hypogastric plexus neurolysis for chronic pelvic pain associated with endometriosis, neuromodulation (dorsal root ganglion stimulation, posterior tibial nerve stimulation, sacral nerve stimulation, and spinal cord stimulation), peritoneal excision (stripping) for endometriosis, and superior hypogastric plexus block with traditional pharmacological treatments experimental, investigational, or unproven. Uterine nerve ablation, laparoscopic uterine nerve ablation and presacral neurectomy are also considered experimental, investigational, or unproven for chronic pelvic pain or other indications. The policy lists related CPT and HCPCS codes, and endometriosis ICD-10 codes, as not covered for the indications it names.
Aetna · Identified Oct 17, 2026Medium impact
Discography (CPB 0733, reviewed 2026-10-15)
Aetna considers lumbar provocative discography medically necessary to evaluate disc pathology in members with persistent, severe low back pain and abnormal interspaces on MRI, when other diagnostic tests have failed to clearly confirm a suspected disc as the source of pain and surgical intervention is being considered. Lumbar provocative discography is experimental, investigational, or unproven for all other indications, including lumbosacral radiculopathy and chronic non-specific back pain when the criteria above are not met. Cervical and thoracic provocative discography, functional anesthetic discography, and contrast disc analysis and mapping are also considered experimental, investigational, or unproven.
Aetna · Identified Oct 16, 2026Medium impact
Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-10-14)
Aetna considers TENS units medically necessary durable medical equipment when used as an adjunct or alternative to drugs for acute post-operative pain in the first 30 days after surgery, or for certain chronic, intractable pain not adequately responsive to other methods. Peripherally implanted nerve stimulators are considered medically necessary for intractable neuropathic pain when all listed criteria are met. Percutaneous electrical nerve stimulation is considered medically necessary for chronic low back pain secondary to degenerative disc disease for up to a 30-day period within a multi-modality rehabilitation program, and for diabetic neuropathy or neuropathic pain that has not responded to listed medications. Many other electrical stimulation devices and indications are listed as experimental, investigational, or unproven.
Aetna · Identified Oct 5, 2026Medium impact
Infrared Therapy (CPB 0604, reviewed 2026-09-09)
Aetna considers infrared coagulation medically necessary for anal dysplasia and for members with grade I, II, or III internal hemorrhoids that are painful or persistently bleeding. Low-level infrared light therapy is considered experimental, investigational, or unproven for a long list of indications, including osteoarthritis, migraines, stroke, and diabetes mellitus, and the infrared glove is unproven for Raynaud's syndrome and all other indications. CPT 46930 is covered when selection criteria are met, while CPT 97026 and HCPCS codes A4639 and E0221 are not covered for the listed indications.
Aetna · Identified Sep 29, 2026Medium impact
Abdominoplasty, Suction Lipectomy, and Ventral Hernia Repair (CPB 0211, reviewed 2026-08-18)
Aetna considers panniculectomy or apronectomy medically necessary when the panniculus hangs below the pubis on high-quality color photographs, the medical records show chronic intertrigo that recurs over 3 months or stays refractory to 3 months of appropriate therapy, and weights have been stable for the most recent 3 months; for bariatric patients, at least 12 months must have elapsed since the bariatric plateau. Repair of a true incisional or ventral hernia is considered medically necessary, and component separation is considered a medically necessary adjunct when a ventral hernia is larger than 10 cm in any direction, involves loss of domain, is 7 to 10 cm wide with a width to rectus abdominis width ratio of 2 or more, is complex with tissue loss, or follows prior failed repairs. Liposuction, lipectomy and excision of excessive skin are considered medically necessary for lipedema of the extremities after pain and disability persist despite 3 months or more of conservative management, and suction lipectomy of the trunk is considered medically necessary for lipedema when the specified pain, functional impairment and conservative-treatment criteria are met. Abdominoplasty, lipoabdominoplasty, suction lipectomy for indications other than lipedema and lymphedema, and panniculectomy that does not meet the criteria are considered cosmetic, repair of diastasis recti is considered not medically necessary, and several ventral hernia techniques, including enhanced-view totally extra-peritoneal repair, TAPPRA and peritoneal flap hernioplasty, are considered experimental, investigational or unproven.
Aetna · Identified Aug 19, 2026Medium impact
Zoledronic Acid (CPB 0524, reviewed 2026-02-12)
Aetna's clinical policy bulletin covers zoledronic acid for commercial medical plans. Zoledronic acid 5 mg (Reclast or generic) is considered medically necessary for postmenopausal osteoporosis, osteoporosis in men, glucocorticoid-induced osteoporosis, Paget's disease of bone, and treatment-related bone loss in men with prostate cancer receiving androgen deprivation therapy, when the listed criteria are met. Zoledronic acid 4 mg (formerly branded Zometa) is considered medically necessary for bone metastases from a solid tumor, certain breast cancer indications, hypercalcemia of malignancy, Langerhans cell histiocytosis with bone disease, multiple myeloma, and systemic mastocytosis with osteopenia or osteoporosis. Aetna considers all other indications experimental, investigational, or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Lumbar Traction Devices (CPB 0569, reviewed 2026-08-06)
Aetna considers autotraction devices, axial spinal unloading devices, home pneumatic lumbar traction devices, inversion tables, lumbar exoskeleton traction devices and lumbar lordotic curve-controlled traction devices experimental, investigational or unproven for low back pain or other indications because their effectiveness has not been established. Medical records must contain sufficient information to show that all applicable coverage criteria are met, and supplier-prepared statements and physician attestations by themselves do not provide sufficient documentation of medical necessity. A Standard Written Order must be communicated to the supplier before a claim is submitted.
Aetna · Identified Aug 18, 2026Medium impact
Laser Neurolysis (CPB 0552, reviewed 2026-08-03)
Aetna considers laser peripheral nerve block (laser neurolysis) experimental, investigational or unproven for carpal tunnel syndrome, complex regional pain syndrome, facet joint pain, phantom limb pain and sacroiliac joint pain, citing insufficient evidence of effectiveness. The list of indications is not all-inclusive. The policy also lists ICD-10 codes for indications it does not cover.
Aetna · Identified Aug 15, 2026Medium impact
Chronic Pelvic Pain, Endometriosis, and Other Indications: Selected Treatments (CPB 0754, reviewed 2025-10-30)
Cannabinoids, hypnotherapy, hypogastric plexus neurolysis for chronic pelvic pain associated with endometriosis, neuromodulation (dorsal root ganglion stimulation, posterior tibial nerve stimulation, sacral nerve stimulation, and spinal cord stimulation), peritoneal excision (stripping) for endometriosis, superior hypogastric plexus block with traditional pharmacological treatments, and uterine nerve ablation, laparoscopic uterine nerve ablation and presacral neurectomy for chronic pelvic pain or other indications are considered experimental, investigational, or unproven because their effectiveness has not been established. The policy lists CPT codes not covered for the indications it lists, including neurostimulator implantation, revision, removal and programming codes, superior hypogastric plexus injection code 64517, and hypnotherapy code 90880, along with ICD-10 diagnosis codes not covered for those indications. Peritoneal excision (stripping) has no specific code in this policy.
Aetna · Identified Aug 14, 2026Medium impact
Pulsed Electromagnetic Stimulation (CPB 0175, reviewed 2026-06-23)
High frequency pulsed electromagnetic stimulation, also called therapeutic magnetic resonance, is considered experimental, investigational or unproven for all indications listed, including acute post-operative pain and edema, bone consolidation, cancer, chronic low back pain, osteoarthritis, osteoporosis, Parkinson's disease, soft tissue injuries, tendinopathy and wounds. Transcutaneous low frequency pulsed electromagnetic stimulation is considered experimental, investigational or unproven for chronic pain including low back pain, fibromyalgia, hand tremors in Parkinson's disease, osteoarthritis, multiple sclerosis spasticity, neuropathic pain and wounds. CPT 0766T and 0767T, and HCPCS E0761, G0295 and G0329, are listed as not covered for the indications in the policy, and intermittent pulsed electromagnetic stimulation for fracture healing is addressed in CPB 0343 Bone Growth Stimulators.
Aetna · Identified Aug 13, 2026Medium impact
Phonophoresis (CPB 0210, reviewed 2026-03-27)
Aetna considers phonophoresis experimental, investigational, or unproven for all indications, including adhesive capsulitis, carpal tunnel syndrome, knee osteoarthritis, low back pain, neck pain, sinusitis, chronic obstructive pulmonary disease, and venous and diabetic ulcers, because its effectiveness has not been established. Controlled clinical trials have failed to demonstrate that phonophoresis increases the rate or extent of absorption of analgesics and anti-inflammatory agents. Bee venom phonophoresis and Contractubex phonophoresis are listed as not covered for the indications in the policy.
Aetna · Identified Aug 13, 2026Medium impact
Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-06-03)
Aetna considers TENS medically necessary durable medical equipment as an adjunct or alternative to drugs for acute post-operative pain in the first 30 days after surgery, or for certain chronic intractable pain not adequately responsive to other methods such as physical therapy and pharmacotherapy. Peripherally implanted nerve stimulators are considered medically necessary for intractable neuropathic pain when the member meets all listed criteria, including a successful percutaneous stimulation trial that resulted in at least a 50% reduction in pain for a minimum of 3 days. TENS for chronic low back pain, PENS for opioid withdrawal, and many other electrical stimulation devices and indications are considered experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Epidural Steroid Injections
Epidural steroid injections may be considered medically necessary as treatment of cervical or lumbar radiculopathy. Reimbursement is limited to a series of three injections in a calendar year at any one level under any and all circumstances. The policy was reviewed on 01/14/2026 with its policy statements unchanged, and ICD-9 procedure and diagnosis codes were removed from the code reference.
Aetna · Identified Nov 4, 2026Low impact
Microwave Thermotherapy (CPB 0682, reviewed 2026-10-26)
Aetna's Microwave Thermotherapy policy (CPB 0682) was reviewed on 2026-10-26, and the source does not state what changed or give a new effective date. It covers microwave thermotherapy as medically necessary only for T1 renal lesions, medically inoperable non-small cell lung cancer lesions under 3 cm, and hepatocellular carcinoma tumors of 3 cm or less, and it lists many other uses (such as breast, pancreatic, bladder, and chronic pain indications) as experimental, investigational or unproven.
Aetna · Identified Aug 15, 2026Low impact
Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2025-10-02)
This is Aetna Clinical Policy Bulletin 0649, reviewed October 2, 2025 and first found by PolicyChanges in August 2026, so it is historical material and the current version should be confirmed before acting. Aetna covers extracorporeal shock-wave therapy only for calcific tendinopathy of the shoulder with a calcium deposit of at least 1 cm lasting 6 months or more after conservative care has failed, and lists dozens of other musculoskeletal, wound and medical uses as experimental, investigational or unproven.

Watch M54.50

Get one email when a payer policy names M54.50, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code M54.50?

There are 16 tracked policy changes affecting code M54.50, including updates from Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code M54.50?

Payers that have issued tracked updates for code M54.50 include: Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code M54.50 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code M54.50. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code M54.50?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Pulsed Radiofrequency (CPB 0735, reviewed 2026-10-21)

Chronic Pelvic Pain and Endometriosis (CPB 0754, reviewed 2026-10-16)

Discography (CPB 0733, reviewed 2026-10-15)

Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-10-14)

Infrared Therapy (CPB 0604, reviewed 2026-09-09)

Abdominoplasty, Suction Lipectomy, and Ventral Hernia Repair (CPB 0211, reviewed 2026-08-18)

Zoledronic Acid (CPB 0524, reviewed 2026-02-12)

Lumbar Traction Devices (CPB 0569, reviewed 2026-08-06)

Laser Neurolysis (CPB 0552, reviewed 2026-08-03)

Chronic Pelvic Pain, Endometriosis, and Other Indications: Selected Treatments (CPB 0754, reviewed 2025-10-30)

Pulsed Electromagnetic Stimulation (CPB 0175, reviewed 2026-06-23)

Phonophoresis (CPB 0210, reviewed 2026-03-27)

Peripheral Electrical Nerve Stimulation for Pain (CPB 0011, reviewed 2026-06-03)

Epidural Steroid Injections

Microwave Thermotherapy (CPB 0682, reviewed 2026-10-26)

Extracorporeal Shock-Wave Therapy for Musculoskeletal Indications and Soft Tissue Injuries (CPB 0649, reviewed 2025-10-02)

What insurance policy changes affect code M54.50?

Which payers have updated policy for code M54.50?

How do I get notified when code M54.50 policy changes?

Why do payers change policies for code M54.50?